A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Telisotuzumab (Primary) ; Cetuximab; Docetaxel; Erlotinib; Fluorouracil; Folinic acid; Irinotecan
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 06 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 29 Jun 2017.
- 05 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.